BeOne Medicines (NASDAQ:ONC) CEO Sells $41,158,986.57 in Stock

Posted by Geri Gentry on Aug 12th, 2026

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) CEO John Oyler sold 115,011 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $357.87, for a total value of $41,158,986.57. Following the sale, the chief executive officer directly owned 125,799 shares in the company, valued at $45,019,688.13. This trade represents a 47.76% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

On Wednesday, August 12th, John Oyler sold 54,892 shares of BeOne Medicines stock. The shares were sold at an average price of $358.15, for a total value of $19,659,569.80.
On Tuesday, August 11th, John Oyler sold 70,907 shares of BeOne Medicines stock. The shares were sold at an average price of $361.90, for a total value of $25,661,243.30.
On Monday, July 20th, John Oyler sold 48,316 shares of BeOne Medicines stock. The shares were sold at an average price of $312.25, for a total value of $15,086,671.00.
On Tuesday, July 21st, John Oyler sold 61,397 shares of BeOne Medicines stock. The stock was sold at an average price of $317.67, for a total transaction of $19,503,984.99.
On Friday, July 10th, John Oyler sold 11,698 shares of BeOne Medicines stock. The shares were sold at an average price of $298.34, for a total transaction of $3,489,981.32.
On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The shares were sold at an average price of $304.35, for a total transaction of $14,767,062.00.
On Tuesday, July 14th, John Oyler sold 145,861 shares of BeOne Medicines stock. The shares were sold at an average price of $305.95, for a total transaction of $44,626,172.95.
On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The stock was sold at an average price of $273.78, for a total transaction of $933,589.80.
On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The stock was sold at an average price of $265.55, for a total transaction of $980,676.15.
On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The shares were sold at an average price of $257.24, for a total transaction of $501,360.76.

BeOne Medicines Price Performance

Shares of ONC traded down $0.22 during mid-day trading on Wednesday, reaching $359.05. 314,911 shares of the stock traded hands, compared to its average volume of 289,218. The firm has a fifty day moving average price of $299.80 and a 200 day moving average price of $308.98. The company has a market cap of $39.39 billion, a price-to-earnings ratio of 63.21 and a beta of 0.49. The company has a current ratio of 3.40, a quick ratio of 3.06 and a debt-to-equity ratio of 0.17. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $253.95 and a 1 year high of $385.22.

BeOne Medicines (NASDAQ:ONC – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.65. The company had revenue of $1.71 billion for the quarter, compared to the consensus estimate of $1.66 billion. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. As a group, equities research analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 7.3 earnings per share for the current year.

Hedge Funds Weigh In On BeOne Medicines

Several institutional investors have recently modified their holdings of ONC. Cetera Investment Advisers purchased a new position in shares of BeOne Medicines during the 2nd quarter valued at about $455,000. Rhumbline Advisers purchased a new position in shares of BeOne Medicines during the second quarter worth approximately $275,000. Arrowstreet Capital Limited Partnership bought a new stake in shares of BeOne Medicines in the 2nd quarter worth approximately $505,000. Invesco Ltd. bought a new stake in shares of BeOne Medicines in the 2nd quarter worth approximately $422,000. Finally, EverSource Wealth Advisors LLC purchased a new stake in shares of BeOne Medicines in the 2nd quarter valued at $68,000. 48.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on ONC shares. Wells Fargo & Company started coverage on BeOne Medicines in a research report on Monday, May 4th. They set an “overweight” rating and a $400.00 price target for the company. Citizens Jmp raised their target price on shares of BeOne Medicines from $396.00 to $405.00 and gave the company a “market outperform” rating in a research note on Thursday, August 6th. Barclays lifted their target price on shares of BeOne Medicines from $403.00 to $407.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Wolfe Research reissued an “outperform” rating and issued a $370.00 price target on shares of BeOne Medicines in a research note on Monday. Finally, Wall Street Zen raised shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 18th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $402.14.

Check Out Our Latest Research Report on ONC

BeOne Medicines Company Profile

(Get Free Report)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.